Last reviewed · How we verify
GLPG1205 film-coated tablets
At a glance
| Generic name | GLPG1205 film-coated tablets |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205 (PHASE1)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG1205 film-coated tablets CI brief — competitive landscape report
- GLPG1205 film-coated tablets updates RSS · CI watch RSS
- Galapagos NV portfolio CI